A ceRNA regulatory network was established to explore potential therapeutic targets in MMD, leading to the identification of AKT1, CLDN3, ISG20, and TGFB2 as critical hypoxia-immune–related genes implicated in disease mechanisms. The gene discussed is AKT1; the disease is multiminicore myopathy.